Biafine Reaches U.S. Market — What the 50-Year Science Shows

Ortho Dermatologics announced on April 14, 2026 that Biafine® Skin Recovery Emulsion is now available for purchase online in the United States, through Amazon and the company's professional direct platform, marking the first time the French pharmacy staple has been broadly accessible to U.S. consumers without a prescription or international order. The product, a trolamine-based oil-in-water emulsion developed in 1971 and sold commercially in France since 1976, has been a fixture in European dermatology and oncology wards for five decades. What the clinical science shows about it is worth understanding before the marketing claims take hold.

The 1971 Formula and the Wound Healing Science It Was Built On

Biafine's origin story is unusually personal. Chemist Paul Wenmaekers created the trolamine emulsion in 1971 to treat burns on a family member; the formula's effectiveness prompted him to pursue regulatory approval. Commercial launch followed in France in 1976. The scientific foundation, however, had been established nearly a decade earlier.

In 1962, British researcher George D. Winter published a paper in Nature demonstrating that partial-thickness wounds in pigs healed roughly twice as fast under a moist polymer film as wounds left open to air. Existing clinical wisdom held that wounds should dry out and form a protective scab. That assumption was wrong. Biafine's oil-in-water emulsion creates precisely the kind of moist wound environment Winter described, maintaining hydration at the wound surface and creating a semi-occlusive barrier against external contamination.

Trolamine's contribution to wound healing goes further than simple moisture retention. Research published in Wound Repair and Regeneration found that Biafine treatment accelerated excisional wound closure in mice, producing superior granulation tissue quality and collagen organization compared to untreated controls. The proposed mechanism: trolamine promotes macrophage recruitment to the wound site. Macrophages are the immune system's generalist repair crew. They clear cellular debris and dead tissue, regulate the transition from inflammatory to proliferative healing phases, and release growth factors that instruct fibroblasts to synthesize collagen. In the cascade of wound repair, recruiting macrophages earlier and in higher concentrations shortens the inflammatory phase and moves the tissue toward remodeling faster.

Does Biafine's Clinical Record Match Its Reputation?

In properly conducted randomized controlled trials, trolamine performs no better than other standard emollient care for radiation-induced dermatitis, its primary clinical application in European oncology for decades.

A 2018 systematic review and meta-analysis published in BMC Cancer pooled data from seven randomized controlled trials comparing trolamine to controls including Aquaphor, calendula cream, and standard institutional moisturizing care in cancer patients undergoing radiotherapy. The pooled result: no statistically significant difference in radiation dermatitis incidence (RR 1.02, 95% CI 0.92–1.14). The GRADE assessment rated the evidence as very low quality. Individual trials produced inconsistent results, with some showing trolamine performing worse than comparison agents on certain severity measures.

This is not evidence that trolamine fails. It is evidence that maintaining any consistently applied, well-tolerated moist environment achieves comparable outcomes in radiation-damaged skin, whether the agent is trolamine, a petrolatum-based ointment, or a ceramide emollient. The active healing variable is the moist wound condition, not the specific product creating it. Biafine's 50-year institutional adoption in France reflects clinical familiarity and a strong safety record more than evidence of superior efficacy.

What Biafine's U.S. Availability Means for Skincare Consumers

For U.S. dermatologists, Biafine's online availability adds a familiar, European-vetted option to post-procedure recovery protocols. For consumers, it offers a noncomedogenic, fragrance-free emollient with decades of clinical safety data. It is relevant for anyone managing minor procedural recovery, acute barrier compromise, or particularly sensitive skin that reacts to preservatives or fragrance compounds common in many U.S. moisturizers.

What it does not offer is mechanistic superiority over ceramide-based barrier repair formulations. The evidence base for ceramide-rich emollients, which restore the stratum corneum's lamellar lipid bilayers by replenishing the physiologic ratio of ceramides, cholesterol, and fatty acids, is specific and well-supported. Trolamine's mechanism targets acute wound healing; ceramide-based formulations address the structural deficit in chronically compromised skin barriers. The two are not in competition. They address different phases of skin repair. For long-term barrier maintenance, the targeted chemistry of modern barrier repair emollients is better matched to the biological problem.

Biafine is not a revelation. It is a well-tolerated 50-year-old French emollient that U.S. consumers can now evaluate on its actual clinical record, rather than through the lens of pharmacy mythology. The macrophage-recruiting mechanism is genuinely interesting. The moist wound healing science it embodies has been validated many times over. The clinical trial data for its most studied application is, by the standards of evidence-based medicine, modest. That combination of real mechanism, 50-year safety record, and mixed controlled trial evidence is an accurate picture of what Biafine is and who it is for.